

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Sodium valproate (Episenta®)	
Indication under review	Bipolar Disorder, Schizo-Affective Disorders	
Policy No:	APC 103	
Date of Issue/Date of re-issue:	May 2013, May 2015	
Review Date:	May 2018	
Policy Statement: The Episenta® brand of sodium valproate is indicated for use in treating patients with bipolar disorder and schizoaffective disorders.		
Traffic Light Status	Amber Initiation on consultant specialist advice.	
Key Points considered:		
<ul style="list-style-type: none"> The committee found no concerns over efficacy or side effects and considers that Episenta® should be the choice of sodium valproate used. 		
References: Original proposal/paper by BHFT, EPC 12 42 September 2012		
Date reviewed by EPC	September 2012	
Expired policy reviewed by APC:	6 th May 2015	
Date Ratified by GP MOC:	17 th June 2015	